Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children with Hutchinson-Gilford Progeria Syndrome

Circulation

Volumn 134, Issue 2, 2016, Pages 114-125

  Gordon, Leslie B ^a,b   Kleinman, Monica E ^a   Massaro, Joe ^c   D'Agostino, Ralph B ^c   Shappell, Heather ^c   Gerhard Herman, Marie ^d   Smoot, Leslie B ^a   Gordon, Catherine M ^e   Cleveland, Robert H ^a   Nazarian, Ara ^f   Snyder, Brian D ^a   Ullrich, Nicole J ^a   Silvera, V Michelle ^a   Liang, Marilyn G ^a   Quinn, Nicolle ^a   Miller, David T ^a   Huh, Susanna Y ^a   Dowton, Anne A ^a   Littlefield, Kelly ^a   Greer, Maya M ^a   Kieran, Mark W ^a   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b BROWN UNIVERSITY   (United States)

^c BOSTON UNIVERSITY   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

aging; atherosclerosis; progeria

Indexed keywords

CALCIUM; CALCIUM PHOSPHATE; LONAFARNIB; PHOSPHOROUS ACID; PRAVASTATIN; PROTEIN; VITAMIN D; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE;

ABDOMINAL PAIN; AGE DISTRIBUTION; ANOREXIA; ARTERIAL WALL THICKNESS; ARTICLE; BONE DENSITY; BONE MINERALIZATION; BRAIN INFARCTION; CALCIUM BLOOD LEVEL; CALORIC INTAKE; CARBOHYDRATE INTAKE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG EFFICACY; ECG ABNORMALITY; FARNESYLATION; FAT INTAKE; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEADACHE; HEART LEFT VENTRICLE HYPERTROPHY; HIP DISLOCATION; HUMAN; HYPERTRANSAMINASEMIA; HYPOCALCEMIA; LEAN BODY WEIGHT; MALE; MECHANICAL TORSION; MINERAL BLOOD LEVEL; MONOTHERAPY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRENYLATION; PRIORITY JOURNAL; PROGERIA; PROTEIN BLOOD LEVEL; PULSE WAVE; RASH; RESTING ENERGY EXPENDITURE; SCHOOL CHILD; SHOULDER DISLOCATION; SKULL FRACTURE; SYSTOLIC BLOOD PRESSURE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; VITAMIN BLOOD LEVEL; VOMITING; WEIGHT GAIN; BONE; CAROTID ARTERY; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIAGNOSTIC IMAGING; DRUG EFFECTS; INFANT; PRESCHOOL CHILD; PROSPECTIVE STUDY; PROTEIN PRENYLATION;

BONE AND BONES; CAROTID ARTERIES; CHILD, PRESCHOOL; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMIDAZOLES; INFANT; MALE; PIPERIDINES; PRAVASTATIN; PROGERIA; PROSPECTIVE STUDIES; PROTEIN PRENYLATION; PYRIDINES;

EID: 84978394046     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.022188     Document Type: Article

References (31)

1. Gordon LB. PRF by the numbers. http://www.progeriaresearch. org. Accessed May17, 2016.
2. Merideth MA, Gordon LB, Clauss S, Sachdev V, Smith AC, Perry MB, Brewer CC, Zalewski C, Kim HJ, Solomon B, Brooks BP, Gerber LH, Turner ML, Domingo DL, Hart TC, Graf J, Reynolds JC, Gropman A, Yanovski JA, Gerhard-Herman M, Collins FS, Nabel EG, Cannon RO 3rd, Gahl WA, Introne WJ. Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med. 2008;358:592-604. doi: 10.1056/NEJMoa0706898.
3. Gordon LB, Massaro J, D'Agostino RB Sr, Campbell SE, Brazier J, Brown WT, Kleinman ME, Kieran MW; Progeria Clinical Trials Collaborative. Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome. Circulation. 2014;130:27-34. doi: 10.1161/CIRCULATIONAHA.113.008285.
4. De Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, Boccaccio I, Lyonnet S, Stewart CL, Munnich A, Le Merrer M, Lévy N. Lamin A truncation in Hutchinson-Gilford progeria. Science. 2003;300:2055. doi: 10.1126/science.1084125.
5. Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, Erdos MR, Robbins CM, Moses TY, Berglund P, Dutra A, Pak E, Durkin S, Csoka AB, Boehnke M, Glover TW, Collins FS. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature. 2003;423:293-298. doi: 10.1038/nature01629.
6. Broers JL, Ramaekers FC, Bonne G, Yaou RB, Hutchison CJ. Nuclear lamins: laminopathies and their role in premature ageing. Physiol Rev. 2006;86:967-1008. doi: 10.1152/physrev. 00047.2005.
7. Sinensky M, Fantle K, Trujillo M, McLain T, Kupfer A, Dalton M. The processing pathway of prelamin A. J Cell Sci. 1994;107(pt 1):61-67.
8. Goldman RD, Shumaker DK, Erdos MR, Eriksson M, Goldman AE, Gordon LB, Gruenbaum Y, Khuon S, Mendez M, Varga R, Collins FS. Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA. 2004;101:8963-8968. doi: 10.1073/pnas.0402943101.
9. Basso AD, Kirschmeier P, Bishop WR. Lipid posttranslational modifications. Farnesyl transferase inhibitors. J Lipid Res. 2006;47:15-31. doi: 10.1194/jlr.R500012-JLR200.
10. Blondel S, Jaskowiak AL, Egesipe AL, Le Corf A, Navarro C, Cordette V, Martinat C, Laabi Y, Djabali K, de Sandre-Giovannoli A, Levy N, Peschanski M, Nissan X. Induced pluripotent stem cells reveal functional differences between drugs currently investigated in patients with Hutchinson-Gilford progeria syndrome. Stem Cells Transl Med. 2014;3:510-519. doi: 10.5966/sctm.2013-0168.
11. Yang SH, Bergo MO, Toth JI, Qiao X, Hu Y, Sandoval S, Meta M, Bendale P, Gelb MH, Young SG, Fong LG. Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation. Proc Natl Acad Sci USA. 2005;102:10291-10296. doi: 10.1073/pnas.0504641102.
12. Glynn MW, Glover TW. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition. Hum Mol Genet. 2005;14:2959-2969. doi: 10.1093/hmg/ddi326.
13. Capell BC, Erdos MR, Madigan JP, Fiordalisi JJ, Varga R, Conneely KN, Gordon LB, Der CJ, Cox AD, Collins FS. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA. 2005;102:12879-12884. doi: 10.1073/pnas.0506001102.
14. Capell BC, Olive M, Erdos MR, Cao K, Faddah DA, Tavarez UL, Conneely KN, Qu X, San H, Ganesh SK, Chen X, Avallone H, Kolodgie FD, Virmani R, Nabel EG, Collins FS. A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model. Proc Natl Acad Sci USA. 2008;105:15902-15907. doi: 10.1073/pnas.0807840105.
15. Fong LG, Frost D, Meta M, Qiao X, Yang SH, Coffinier C, Young SG. A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science. 2006;311:1621-1623. doi: 10.1126/science.1124875.
16. Yang SH, Meta M, Qiao X, Frost D, Bauch J, Coffinier C, Majumdar S, Bergo MO, Young SG, Fong LG. A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation. J Clin Invest. 2006;116:2115-2121. doi: 10.1172/JCI28968.
17. Gordon LB, Kleinman ME, Miller DT, Neuberg DS, Giobbie-Hurder A, Gerhard-Herman M, Smoot LB, Gordon CM, Cleveland R, Snyder BD, Fligor B, Bishop WR, Statkevich P, Regen A, Sonis A, Riley S, Ploski C, Correia A, Quinn N, Ullrich NJ, Nazarian A, Liang MG, Huh SY, Schwartzman A, Kieran MW. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA. 2012;109:16666-16671. doi: 10.1073/pnas.1202529109.
18. Ullrich NJ, Kieran MW, Miller DT, Gordon LB, Cho YJ, Silvera VM, Giobbie-Hurder A, Neuberg D, Kleinman ME. Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment. Neurology. 2013;81:427-430. doi: 10.1212/WNL.0b013e31829d85c0.
19. Varela I, Pereira S, Ugalde AP, Navarro CL, Suárez MF, Cau P, Cadinanõs J, Osorio FG, Foray N, Cobo J, de Carlos F, Lévy N, Freije JM, López-Otín C. Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat Med. 2008;14:767-772. doi: 10.1038/nm1786.
20. Gordon LB, McCarten KM, Giobbie-Hurder A, Machan JT, Campbell SE, Berns SD, Kieran MW. Disease progression in Hutchinson-Gilford progeria syndrome: impact on growth and development. Pediatrics. 2007;120:824-833. doi: 10.1542/peds.2007-1357.
21. Gerhard-Herman M, Smoot LB, Wake N, Kieran MW, Kleinman ME, Miller DT, Schwartzman A, Giobbie-Hurder A, Neuberg D, Gordon LB. Mechanisms of premature vascular aging in children with Hutchinson-Gilford progeria syndrome. Hypertension. 2012;59:92-97. doi: 10.1161/HYPERTENSIONAHA.111.180919.
22. Cleveland RH, Gordon LB, Kleinman ME, Miller DT, Gordon CM, Snyder BD, Nazarian A, Giobbie-Hurder A, Neuberg D, Kieran MW. A prospective study of radiographic manifestations in Hutchinson-Gilford progeria syndrome. Pediatr Radiol. 2012;42:1089-1098. doi: 10.1007/s00247-012-2423-1.
23. Gordon CM, Gordon LB, Snyder BD, Nazarian A, Quinn N, Huh S, Giobbie-Hurder A, Neuberg D, Cleveland R, Kleinman M, Miller DT, Kieran MW. Hutchinson-Gilford progeria is a skeletal dysplasia. J Bone Miner Res. 2011;26:1670-1679. doi: 10.1002/jbmr.392.
24. Kieran MW, Packer RJ, Onar A, Blaney SM, Phillips P, Pollack IF, Geyer JR, Gururangan S, Banerjee A, Goldman S, Turner CD, Belasco JB, Broniscer A, Zhu Y, Frank E, Kirschmeier P, Statkevich P, Yver A, Boyett JM, Kun LE. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. J Clin Oncol. 2007;25:3137-3143. doi: 10.1200/JCO.2006.09.4243.
25. Munns CF, Rajab MH, Hong J, Briody J, Högler W, McQuade M, Little DG, Cowell CT. Acute phase response and mineral status following low dose intravenous zoledronic acid in children. Bone. 2007;41:366-370. doi: 10.1016/j.bone.2007.05.002.
26. Wohlin M, Sundström J, Andrén B, Larsson A, Lind L. An echolucent carotid artery intima-media complex is a new and independent predictor of mortality in an elderly male cohort. Atherosclerosis. 2009;205:486-491. doi: 10.1016/j.atherosclerosis. 2009.01.032.
27. Zhang J, Lian Q, Zhu G, Zhou F, Sui L, Tan C, Mutalif RA, Navasankari R, Zhang Y, Tse HF, Stewart CL, Colman A. A human iPSC model of Hutchinson Gilford progeria reveals vascular smooth muscle and mesenchymal stem cell defects. Cell Stem Cell. 2011;8:31-45. doi: 10.1016/j.stem.2010.12.002.
28. Villa-Bellosta R, Rivera-Torres J, Osorio FG, Acín-Pérez R, Enriquez JA, López-Otín C, Andrés V. Defective extracellular pyrophosphate metabolism promotes vascular calcification in a mouse model of Hutchinson-Gilford progeria syndrome that is ameliorated on pyrophosphate treatment. Circulation. 2013;127:2442-2451. doi: 10.1161/CIRCULATIONAHA.112.000571.
29. Scaffidi P, Misteli T. Lamin A-dependent misregulation of adult stem cells associated with accelerated ageing. Nat Cell Biol. 2008;10:452-459. doi: 10.1038/ncb1708.
30. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31:607-617.
31. Gordon LB, Kleinman ME, Kieran MW, Misteli T. The decisionmaking process and criteria in selecting candidate drugs for progeria clinical trials [published online ahead of print May 26, 2016]. EMBO J. doi: 10.15252/emmm.201606280. http://embomolmed.embopress.org/content/early/2016/05/26/emmm.201606280.long. Accessed May 17, 2016.